| Code | CSB-RA003995MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TUR03, targeting complement component 5 (C5), a critical protein in the complement cascade of the innate immune system. C5 plays a pivotal role in immune defense by facilitating the formation of the membrane attack complex (MAC) and generating the potent anaphylatoxin C5a upon cleavage. Dysregulation of C5 activation is implicated in numerous complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis, and neuromyelitis optica spectrum disorders. Excessive C5 activity contributes to inflammatory tissue damage, hemolysis, and thrombotic complications in these conditions.
TUR03 represents a therapeutic antibody designed to inhibit C5 cleavage, thereby preventing downstream complement activation and associated pathological effects. This biosimilar provides researchers with a valuable tool for investigating complement-mediated pathophysiology, studying C5-dependent immune responses, and exploring potential therapeutic interventions in complement-related diseases. The antibody supports various experimental approaches in immunology, inflammation research, and translational medicine studies.
There are currently no reviews for this product.